Efficacy and Safety of Half Dose Alteplase Added to Heparine, in Patients With Moderate Pulmonary Embolism

NCT ID: NCT02604238

Last Updated: 2024-02-08

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE3
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-03-31
• Study Completion Date: 2016-03-31

Brief Summary

The primary aim of this study is to evaluate whether mid dose (safe dose) of Alteplase in addition to standard treatment with heparin (LMWH) in patients with pulmonary embolism (PE) at intermediate risk, it is effective to reduce:

• right ventricular dysfunction
• pulmonary hypertension 24 hours and 7 days after the treatment
• PE recurrence to 7days and 30 days after the treatment without increasing the incidence of bleeding intra-extracranial

Detailed Description

The guidelines of the European Society of Cardiology (ESC2014) confirm the indication for pharmacological revascularization with thrombolysis only to cases of pulmonary embolism at high risk and thus hemodynamically unstable (class of recommendation I, level of evidence B), reserving the surgical or interventional procedures to cases where thrombolysis has failed or is contraindicated, while it remains controversial the role of thrombolysis in patients with pulmonary embolism at intermediate risk; the current state, in EP intermediate risk, the standard treatment involves the administration of low molecular weight heparin (LMWH), or fondaparinux (for 5-10 days followed by anticoagulation therapy with vitamin K antagonists) or alternatively the new anticoagulants oral (NAO). Although the results of the study PEITHO, recently published, confirm the indication for thrombolytic therapy for primary reperfusion in patients with embolism pulmonary high risk and provide element of reflection about the incidence of intracranial hemorrhage major, recent studies suggest that the thrombolysis with tPA to reduced dose (about half the dose that used in standard thrombolysis) in addition to anticoagulants (low molecular weight heparin) may reduce pulmonary hypertension (systolic artery pulmonary pressure> 40 mmHg) and the incidence of recurrent PE. In this protocol, based on the study MOPETT and pharmacokinetic data available, it is used a "safe dose" (safe dose reduced) of alteplase which provides a intravenous (iv) bolus loading dose of 10 mg in 1 min, followed by intravenous infusion 40 mg within two hours (for patients weighing <50 kg loading dose iv bolus of 0.5 mg in 1 min, followed by iv infusion of 40 mg within two hours).

After treatment with alteplase, the heparin therapy will be resumed when aPTT values are less than twice the upper limit of normal; the infusion will be adjusted to maintain aPTT between 50-70 seconds (1.5 to 2.5 times the reference value), and for safety reasons are excluded patients> 65 -70 years (increased risk of bleeding complications related age and comorbidities).

Conditions

Pulmonary Embolism

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Group A

Administered a "safe dose" of Alteplase. All patients are treated with low molecular weight heparin ( LMWH ) according to the Guidelines ESC2014 heparin in addition it is administered a "safe dose" of Alteplase.

Group Type: EXPERIMENTAL

Alteplase

Intervention Type: DRUG

Enoxaparin (1mg) 100UI aXa/kg/sc \[LMWH\], 15 -30 minutes prior to administration of intravenous (iv) bolus loading dose of 10 mg in 1 min, followed by iv infusion of 40 mg within two hours (for patients weighing \<50 kg, a loading dose of bolus of 0.5 mg in 1 min, followed by iv infusion of 40 mg in two hours); the infusion will be adjusted to maintain the value of aPTT between 50-70 seconds (1.5 to 2.5 times the reference value).

Group B

All patients are treated with low molecular weight heparin ( LMWH ) according to the Guidelines ESC2014 heparin. It not added any treatment.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Alteplase

Enoxaparin (1mg) 100UI aXa/kg/sc \[LMWH\], 15 -30 minutes prior to administration of intravenous (iv) bolus loading dose of 10 mg in 1 min, followed by iv infusion of 40 mg within two hours (for patients weighing \<50 kg, a loading dose of bolus of 0.5 mg in 1 min, followed by iv infusion of 40 mg in two hours); the infusion will be adjusted to maintain the value of aPTT between 50-70 seconds (1.5 to 2.5 times the reference value).

Intervention Type: DRUG

Other Intervention Names

tPA-tissue Plasminigen Activator

Eligibility Criteria

Inclusion Criteria

1. pulmonary embolism at intermediate risk as defined by the Guidelines ESC2014[ documented pulmonary CT angiography]

2. pulmonary hypertension (systolic pulmonary pressure greater or equal to 40 mm Hg) [documented echocardiogram presence of thrombotic material in the right-sided]

3. disfunction Ventricular right confirmed by echocardiogram or TC chest:

• dilation of the right sections (> 30 mm in parasternal or relationship right ventricle/left ventricle > 1)
• paradoxical movement of the interventricular septum
• TAPSE reduced (Tricuspid Annular Plane Systolic Excursion)
• tricuspid regurgitation with gradient VD/AD> 30 mmHg, in the absence of right ventricular hypertrophy, McConnell sign (apical segment of the free wall of the right ventricle normalKinetic or hyperkinetic than a hypokinesia or akinesia of the remaining parts of the right ventricular wall),

4. myocardial damage confirmed with:

• Troponin I or T positive
• higt value of the biomarkers of myocardial damage : BNP or NTproBNP

5. informed consent

Exclusion Criteria

1. age <18 years and> 65 years

2. HASBLED score ≥ 3 (23)

3. intracranial tumors

4. ischemic stroke within 2 months

5. surgery neurological within 1 month and surgery within 10 days

6. trauma within 15 days

7. hypotension to hospitalization (systemic blood pressure <90 mmHg)

8. uncontrolled hypertension (SBP> 180mmHg and PAD> 110mmHg)

9. clotting disorders

10. thrombocytopenia (<100.000)

11. platelet counts below 100 × 109 /L severe thrombocytopenia (platelet count <50.000 ptl / mm3)

12. liver failure

13. kidney failure

14. gastrointestinal bleeding within 10 days

15. pregnancy or childbirth within 30 days

16. contraindications to the use of thrombolytics

17. contraindications to the use of low molecular weight heparin (enoxaparin)

18. anticoagulation therapy started more than 8 hours

19. COPD

20. endocarditis

21. severe obesity

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Azienda U.S.L. 1 di Massa e Carrara

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Alberto Conti, MD

Role: PRINCIPAL_INVESTIGATOR

Azienda USL1 di Massa e Carrara

Other Identifiers

Azienda USL1 Massa e Carrara

Identifier Type: -

Identifier Source: org_study_id